The present investigation was designed to determine whether atrial natriuretic peptides consisting of amino acids 1\p=n-\30 (long acting natriuretic peptide), 31\p=n-\67 (vessel dilator) and 79\p=n-\98 (kaliuretic peptide) as well as 99\p=n-\126 (atrial natriuretic factor (ANF)) of the 126 amino acid ANF prohormone inhibit aldosterone secretion. Thirty healthy human subjects were studied following infusion of 100 ng/kg body weight/min for 60 min of each of the respective peptides. Kaliuretic 
Introduction
The most important regulators of aldosterone secretion are the renin-angiotensin system and potassium (Quinn & Williams 1988) . Atrial natriuretic factor has been found to be a potent in vivo and in vitro inhibitor of aldosterone secretion via a direct effect on the adrenal (Atarashi et al. 1984, Burnett et al. 1984 , Chartier et al. 1984 , Goodfrield et al. 1984 , Kudo & Baird 1984 , Campbell et al. 1985 , Espiner et al. 1985 , Hirata et al. 1985 , Anderson et al. 1986 , Higuchi et al. 1986 , Aguilar 1987 , Denker et al. 1990 , Clark et al. 1992 ) and indirectly through inhibition of remn release (Burnett et al. 1984 , Maack et al. 1984 , Kurtz et al. 1986 , Vari et al. 1986 ). Atrial natriuretic factor also enhances potassium excretion in both animals (Martin et al. 1990 ) and humans (Vesely et al. 19946 ) with the resultant change in the circulating potassium concentration possibly also contributing to the decreased aldosterone secretion that has been observed.
Atrial natriuretic factor (ANF) consists of amino acids 99-126 of the atrial natriuretic factor prohormone. At least three other peptide hormones are derived from this same prohormone (Martin et al. 1990 , Gower et al. 199A, Vesely et al. 1994a . These peptides, consisting of amino acids 1-30 (pro ANF 1-30; long acting natriuretic peptide), vessel (Martin et al. 1990 ) and humans (Vesely et al. 1994e) . Of the four peptide hormones derived from the ANF prohormone, kaliuretic peptide has the most potent effect on potassium metabolism in both humans (Vesely et al. 1994i> ) and animals (Martin et al. 1990 (Fig. 1) . Within 30 min of cessation of the ANF infusion, the concentration of aldosterone had returned to its pre-infusion values (Fig. 1) .
In the control subjects who received vehicle only, plasma aldosterone concentration increased during the infusion period, remained elevated at 30 min, and returned to its pre-infusion values by 60 min post-infusion (Fig. 1) . Kaliuretic peptide caused a 6-fold decrease in plasma aldosterone concentration (the most of any of the atrial peptides) within the first 20 min of infusion and the concentration remained significantly decreased ( < 01) three hours after cessation of the kaliuretic peptide infusion (Fig. 1) . Long acting natriuretic peptide decreased plasma aldosterone during its infusion and levels remained significantly ( <0 01) decreased 3 h after stopping the infusion (Fig. 1) . Vessel dilator did not significantly decrease plasma aldosterone levels (Fig. 1) (Higuchi et al. 1989 ). Potassium-stimulated aldoster¬ one secretion is also markedly inhibited by atrial natriu¬ retic factor (Takagi et al. 1986 , Clark et al. 1992 Kaliuretic peptide was found to be an even more potent inhibitor than ANF of aldosterone secretion in healthy humans when both were directly compared at identical concentrations. In these same subjects, kahuretic peptide has stronger potassium excreting properties than ANF (Vesely et al. 19946 ). These findings (Vesely et al. 199Ab) suggest that the inhibitory effects of kahuretic peptide (and ANF) on aldosterone secretion may involve modification of potassium metabolism as well as a direct effect. In the present investigation, however, plasma potassium did not change following administration of any of the atrial pep¬ tides suggesting that all of their effects on aldosterone secretion are direct. The data of the present investigations do not, however, completely rule out the possibility that kahuretic peptide may inhibit potassium-stimulated aldos¬ terone secretion as well as directly inhibiting aldosterone secretion since infusion of 10 meq potassium, which does not change the measured plasma potassium concentration, increases plasma aldosterone concentration by 25% (Takagi et al. 1986 ). Thus aldosterone secretion appears to be regulated by very small changes in potassium, which are not always measurable with potassium assays (Takagi et al. 1986 ).
With respect to kaliuretic peptide's effect on aldoster¬ one secretion, it is important to note that both ANF and kaliuretic peptide are released simultaneously following physiological stimuli such as those induced with central hypervolemia secondary to head-out of water immersion (Vesely et al. 1995) . Both ANF and kaliuretic peptide circulate normally in healthy humans, but kaliuretic pep¬ tide circulates at 3-fold higher concentrations than ANF (Vesely et al. 1994b (Vesely et al. , 1995 . Since kahuretic peptide had greater inhibitory effects than ANF in the present investigation, where they were compared at the same (Denker et al. 1990 ). LANP and vessel dilator are released simultaneously with ANF from isolated perfused atria (Dietz et al. 1991) . They are also released simultaneously with ANF in response to a sodium load in vitro (Dietz et al. 1992 ) and following central hypervolemia in humans (Vesely et al. 1989) , their concentrations in the circulation being 10-to 15-fold higher than ANF (Winters et al. 1989 ). The fact that LANP inhibited aldosterone secretion for a significantly (P<0001) longer period than ANF plus the fact that LANP circulates at 15-fold higher concentrations than ANF (Winters et al. 1989 , Gower et al. 1994 suggests that LANP, along with kahuretic peptide, may be an important physiological regulator of aldosterone secretion. Vessel dilator had no effect on aldosterone secretion in any of the human subjects in the present investigation. The lack of effect of vessel dilator in vivo is in agreement with the in vitro study where it had no effect on aldosterone secretion from isolated adrenal cells (Denker et al. 1990 ).
The renin-angiotensin system is modified by a number of factors, one of-which is the adrenergic nervous system. Activation of the adrenergic nervous system caused by the mental stress of participating in a study in which the subjects did not know if they were receiving placebo (vehicle only) or one of the active peptides, is the most hkely reason why plasma aldosterone increased in the control subjects. The ability of the atrial peptides to inhibit aldosterone secretion in light of the probable same acti¬ vation of the adrenergic nervous system in the subjects receiving the peptide infusions indicates that their effects are stronger on the renin-aldosterone system than the influence of the adrenergic nervous system on the reninaldosterone system. In summary, this investigation dem¬ onstrates that three peptides derived from the ANF prohormone decrease aldosterone secretion, and that both kaliuretic peptide and long acting natriuretic peptide inhibit aldosterone secretion for a significantly longer period than ANF.
